Allergan profit falls as Botox sales slump

By Staff Writers
Thursday, 28 April, 2005

Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.

First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.

Net sales rose to $527 million, from $472 million in the year earlier period.

Botox sales were $176 million, about $10 million short of analyst views.

Related News

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd